Skip to main content

Recombinant Human Flt-3 Ligand/FLT3L Protein

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-34868

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP2-34868-100ug
NBP2-34868-10ug
NBP2-34868-1mg
NBP2-34868-500ug

Key Product Details

Source

E. coli

Accession #

Conjugate

Unconjugated

Applications

Bioactivity, SDS-PAGE

Product Specifications

Description

A single non-glycosylated polypeptide chain containing 155 amino acids corresponding to Flt-3 Ligand/FLT3L Source: E. coli

Uniprot ID: P49771

Amino Acid Sequence: TQDCSFQHSP ISSDFAVKIR ELSDYLLQDY PVTVASNLQD EELCGGLWRL VLAQRWMERL KTVAGSKMQG LLERVNTEIH FVTKCAFQPP PSCLRFVQTN ISRLLQETSE QLVALKPWIT RQNFSRCLEL QCQPDSSTLP PPWSPRPLEA TAPTA

Purity

> 97 % pure by SDS-PAGE and HPLC

Endotoxin Level

Less than 1 EU/ug of Flt-3 Ligand/FLT3L as determined by LAL method.

Predicted Molecular Mass

17.6 kDa.
Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Activity

Flt3 Ligand protein is fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using human AML5 cells is less than 1.0 ng/ml, corresponding to a specific activity of > 1.0 x 10^6 IU/mg.

Protein / Peptide Type

Recombinant Protein

Scientific Data Images for Recombinant Human Flt-3 Ligand/FLT3L Protein

SDS-PAGE: Recombinant Human Flt-3 Ligand/FLT3L Protein [NBP2-34868]

SDS-PAGE: Recombinant Human Flt-3 Ligand/FLT3L Protein [NBP2-34868]

SDS-Page: Human Flt-3 Ligand Protein [NBP2-34868]

Formulation, Preparation and Storage

NBP2-34868
Formulation Lyophilized from a 0.2 um filtered concentrated solution in PBS, pH 7.0.
Preservative No Preservative
Concentration Lyoph
Reconstitution Recommended to centrifuge prior to opening. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/mL. Apportion stock solutions into working aliquots and store at
Format Carrier-Free
Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Store at -20 to -70C as supplied. After reconstitution, store at 2 to 8C for 1 month and at -20 to -70C for long term storage. Avoid repeated freeze-thaw cycles.

Background: Flt-3 Ligand/FLT3L

Flt-3 Ligand promotes the differentiation of multiple hematopoietic cell lineages. Flt-3 Ligand is expressed as a noncovalently-linked dimer by T cells and bone marrow and thymic fibroblasts. Both transmembrane and soluble forms of Flt-3 Ligand signal through the tyrosine kinase receptor Flt-3/Flk-2. Flt-3 Ligand induces the expansion of monocytes and immature dendritic cells, B cell differentiation, NK cell development, and myeloid differentiation of hematopoietic stem cells. The mouse and human proteins show cross-species activity.

Long Name

fms-like Tyrosine Kinase 3 Ligand

Alternate Names

FLG3L, Flt3L, FLT3LG

Gene Symbol

FLT3LG

UniProt

Additional Flt-3 Ligand/FLT3L Products

Product Documents for Recombinant Human Flt-3 Ligand/FLT3L Protein

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Recombinant Human Flt-3 Ligand/FLT3L Protein

This lyophilized preparation is stable for 12 months from date of receipt at -20 to -70 degrees C, preferably desiccated. Upon reconstitution, the preparation can be stored for 1 month at 2-8 degrees C under sterile conditions, and for 3 months at -20 degrees C to -70 degrees C. Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Stock solutions should be aliquoted and stored at < -20 degrees C. Further dilutions should be made in appropriate buffered solutions

This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...